The human ovary, in particular the corpus luteum, secretes significant amounts of dimeric and therefore biologically active inhibin.

No abstract

No abstract

No abstract

No abstract

Inhibin is a polypeptide hormone produced by the granulosa cells of the ovary, and is present in body as dimers of vanous sies each compnsng an a-and a-subunit. Free forms of the a-subunit also circulate, and the presently available radioimmunoassay (Monash asy) cannot distinguish these from biologicaly active dimeric inhibin. Recently we described a new two-site enzyme immunoassay able for the first time to measure the kvels of dimeric inhibin throughout the human menstrual cycle. The sensitivity limit of this assay is 2 pg ml-' in human serum with cross-reactivity against activin of 0.05%. The normal range of inhibin in post-menopausal women is <5 pg mll, in pre-menopausal women 2 -80 pg ml (2 -10 pg ml iin the follicular phase, 40 -80 pg ml-' in the luteal phase). This assay was used to determine inhibin levels in sera from 15 (five pre-menopausal and ten post-menopausal) patients with granulosa cell tumours of the ovary. It was raised in a pre-menopausal patient preoperatively (261 pg ml -), in six post-menopausal patients (32, 43, 54, 66, 24

Fewer than 40% intrapartum deliveries by caesarean section for fetal distress were achieved within 30 minutes of the decision, despite that being the unit standard. There was, however, no evidence to indicate that overall an interval up to 120 minutes was detrimental to the neonate unless the delivery was a 'crash' caesarean section. These data thus do not provide evidence to sustain the recommendation of a standard of 30 minutes for intrapartum delivery by caesarean section.

Genetic changes have been shown to be important in determining the multistep progression of cancer. Allele loss studies and karyotypic analysis of epithelial ovarian tumours have indicated the presence of putative tumour suppressor genes on chromosomes 6, 11, 13, 17, 18, 22, and X. We have focused on chromosome arm 6q to identify the minimal region that may contain a putative tumour suppressor gene. Nineteen polymorphic microsatellite markers from 6q and one centromeric marker (D6S294) have been used to detect allele loss in 68 ovarian tumours (six benign, six borderline, and 56 with malignant histology). Allele loss was evaluated by separation of fluorescence labelled polymerase chain reaction-amplified products. Forty-six of fifty-six (82%) malignant tumours showed allele loss on 6q, whereas only four of 56 had lost all the markers tested. Forty-one of fifty-six (73%) malignant tumours showed allele loss at 6q26-27. The minimal region of allele loss was between markers D6S264 and D6S297 (3 cM), with maximal allele loss of 62% at D6S193 and 52% at D6S297. Three tumours showed loss of D6S193 only, while retaining flanking informative markers. Allele loss around 6q26-27 was observed in all histological types of epithelial ovarian cancer and did not correlate with any clinical factors. In addition, there was allele loss at ESR (56%) and D6S286 (47%), though a minimal region was not defined. Allele loss at 6q12-25 correlated significantly with endometrioid and mucinous ovarian malignant tumours (P = 0.01). The physical mapping of the region between D6S297 and D6S264 will allow the eventual identification of the putative tumour suppressor gene.